Cargando…

Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone

Poor bioavailability of eye drops is a well-known issue, which can be improved by increasing the residence time on the eye surface and the penetration of the active pharmaceutical ingredient (API). This study aims to formulate in situ gelling mucoadhesive ophthalmic preparations. To increase the res...

Descripción completa

Detalles Bibliográficos
Autores principales: Szalai, Boglárka, Jójárt-Laczkovich, Orsolya, Kovács, Anita, Berkó, Szilvia, Balogh, György Tibor, Katona, Gábor, Budai-Szűcs, Mária
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498616/
https://www.ncbi.nlm.nih.gov/pubmed/36135271
http://dx.doi.org/10.3390/gels8090561
_version_ 1784794804415102976
author Szalai, Boglárka
Jójárt-Laczkovich, Orsolya
Kovács, Anita
Berkó, Szilvia
Balogh, György Tibor
Katona, Gábor
Budai-Szűcs, Mária
author_facet Szalai, Boglárka
Jójárt-Laczkovich, Orsolya
Kovács, Anita
Berkó, Szilvia
Balogh, György Tibor
Katona, Gábor
Budai-Szűcs, Mária
author_sort Szalai, Boglárka
collection PubMed
description Poor bioavailability of eye drops is a well-known issue, which can be improved by increasing the residence time on the eye surface and the penetration of the active pharmaceutical ingredient (API). This study aims to formulate in situ gelling mucoadhesive ophthalmic preparations. To increase the residence time, the formulations were based on a thermosensitive polymer (Poloxamer 407 (P407)) and were combined with two types of mucoadhesive polymers. Dexamethasone (DXM) was solubilized by complexation with cyclodextrins (CD). The effect of the composition on the gel structure, mucoadhesion, dissolution, and permeability was investigated with 3(3) full factorial design. These parameters of the gels were measured by rheological studies, tensile test, dialysis membrane diffusion, and in vitro permeability assay. The dissolution and permeability of the gels were also compared with DXM suspension and CD-DXM solution. The gelation is strongly determined by P407; however, the mucoadhesive polymers also influenced it. Mucoadhesion increased with the polymer concentration. The first phase of drug release was similar to that of the CD-DXM solution, then it became prolonged. The permeability of DXM was significantly improved. The factorial design helped to identify the most important factors, thereby facilitating the formulation of a suitable carrier for the CD-DXM complex.
format Online
Article
Text
id pubmed-9498616
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94986162022-09-23 Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone Szalai, Boglárka Jójárt-Laczkovich, Orsolya Kovács, Anita Berkó, Szilvia Balogh, György Tibor Katona, Gábor Budai-Szűcs, Mária Gels Article Poor bioavailability of eye drops is a well-known issue, which can be improved by increasing the residence time on the eye surface and the penetration of the active pharmaceutical ingredient (API). This study aims to formulate in situ gelling mucoadhesive ophthalmic preparations. To increase the residence time, the formulations were based on a thermosensitive polymer (Poloxamer 407 (P407)) and were combined with two types of mucoadhesive polymers. Dexamethasone (DXM) was solubilized by complexation with cyclodextrins (CD). The effect of the composition on the gel structure, mucoadhesion, dissolution, and permeability was investigated with 3(3) full factorial design. These parameters of the gels were measured by rheological studies, tensile test, dialysis membrane diffusion, and in vitro permeability assay. The dissolution and permeability of the gels were also compared with DXM suspension and CD-DXM solution. The gelation is strongly determined by P407; however, the mucoadhesive polymers also influenced it. Mucoadhesion increased with the polymer concentration. The first phase of drug release was similar to that of the CD-DXM solution, then it became prolonged. The permeability of DXM was significantly improved. The factorial design helped to identify the most important factors, thereby facilitating the formulation of a suitable carrier for the CD-DXM complex. MDPI 2022-09-02 /pmc/articles/PMC9498616/ /pubmed/36135271 http://dx.doi.org/10.3390/gels8090561 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Szalai, Boglárka
Jójárt-Laczkovich, Orsolya
Kovács, Anita
Berkó, Szilvia
Balogh, György Tibor
Katona, Gábor
Budai-Szűcs, Mária
Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone
title Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone
title_full Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone
title_fullStr Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone
title_full_unstemmed Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone
title_short Design and Optimization of In Situ Gelling Mucoadhesive Eye Drops Containing Dexamethasone
title_sort design and optimization of in situ gelling mucoadhesive eye drops containing dexamethasone
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498616/
https://www.ncbi.nlm.nih.gov/pubmed/36135271
http://dx.doi.org/10.3390/gels8090561
work_keys_str_mv AT szalaiboglarka designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone
AT jojartlaczkovichorsolya designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone
AT kovacsanita designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone
AT berkoszilvia designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone
AT baloghgyorgytibor designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone
AT katonagabor designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone
AT budaiszucsmaria designandoptimizationofinsitugellingmucoadhesiveeyedropscontainingdexamethasone